ESC 2016: Applying Novel Therapeutics to Improve Outcomes in Patients with Pulmonary Arterial Hypertension

This CME program will cover data on current and emerging therapeutic options for treating patients with pulmonary arterial hypertension (PAH) that was presented at the European Society of Cardiology 2016 Annual Congress held in Rome, Italy. The expert faculty will discuss recent clinical trial data on pulmonary arterial hypertension along with ways to integrate new information into daily practice. Clinicians will gain a better understanding of ways to improve outcomes for their patients with PAH by providing the most up-to-date care.

TARGET AUDIENCE

Cardiologists, primary care physicians, nurse practitioners, and other healthcare professionals who care for patients with pulmonary arterial hypertension.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to the following:

  1. Understand the application of current and emerging therapeutic options for treating pulmonary arterial hypertension
  2. Analyze data from clinical trials on pulmonary arterial hypertension therapeutics
  3. Integrate new data into clinical practice to lower risks and improve outcomes in patients with pulmonary arterial hypertension

FACULTY

Ioana Preston, MD
Pulmonary Function Lab Director
Director, Pulmonary Hypertension Center
Associate Professor, Tufts University School of Medicine
Boston, MA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Ioana Preston, MD

Consultant/Advisor: Actelion Pharmaceuticals US, Inc.; Bayer AG; Gilead; Pfizer Inc.

Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Bayer AG; Gilead; United Therapeutics Corporation

Speakers Bureau: Genentech, Inc.

Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Chelsey Benedek; Nicole Brestowski; Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Adams hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Financial Support

This CME activity has been supported by an independent educational grant from Actelion Pharmaceuticals US, Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME and Actelion Pharmaceuticals US, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
12/29/2016
Course expires: 
12/28/2017
Rating: 
4

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
12/29/2016
Course expires: 
12/28/2017
Please login or register to take this course.